“ONE FAMILY’S STORY” John Emond, NASA Headquarters Human Interest Panel FLC Mid-Atlantic Region Annual Conference September 16, 2009

GRIM STATISTICS MENWOMEN TOTAL CASES: 766,130TOTAL CASES: 713,220 TOTAL DEATHS: 292,540TOTAL DEATHS: 269,800 CASE BY TYPE: Prostate 25% Lung and Bronchus 15% Colon and Rectum 10% Urinary Bladder 7% Skin Melanoma 5% Non-Hodgkin's Lymphoma 5% CASE BY TYPE: Breast 27% Lung and Bronchus 14% Colon and Rectum 10% Uterine 6% Non-Hodgkin's Lymphoma 4% Skin Melanoma 4% DEATH BY TYPE: Lung and Bronchus 30% Prostate 9% Colon and Rectum 9% Pancreas 6% Leukemia 4% DEATH BY TYPE: Lung and Bronchus 26% Breast 15% Colon and Rectum 9% Pancreas 6% Ovary 5% 2009 ESTIMATED U.S. CANCER CASES AND DEATHS Source: American Cancer Society 2

LIFETIME PROBABILITY DEVELOPING CANCER, DATA Source: NIH/NCI MENWOMEN ALL TYPES OF CANCER: 1 IN 2ALL TYPES OF CANCER: 1 IN 3 PROSTATE: 1 IN 6BREAST: 1 IN 8 3

John and Mary Brough Emond Brough/Emond Family Does Not Need Statistics John and Dolores Brough, Parents 9 sons and daughters Joseph and Ellen Emond, Parents 3 sons John Brough died brain cancer age 53 Son Joseph: Treated for prostate cancer Daughter Dolores: Treated for breast cancer Husband William: Treated for Non-Hodgkin's Lymphoma Son James: Treated for prostate cancer Son John: Treated for Non-Hodgkin's Lymphoma Son John: Diagnosed with prostate cancer, May 2009 Son Vincent: Treated for bladder cancer Daughter Maureen: Treated for basal skin cancer 4

Early Detection Annual checkup March 2009 yielded substantial spike in Prostate-Specific Antigen (PSA) level in blood Subsequent blood tests confirmed elevated PSA level, additional testing required Joined an NIH clinical study April, 2009 for prostate analysis 5

NIH/PHILIPS MEDICAL SYSTEMS COLLABORATION NIH study merges MR imaging and biopsy to more accurately detect possible presence of prostate cancer. I was 95 th participant in study Collaboration between NIH and Philips Medical Systems (CRADA 01864) with NIH Drs. Peter Pinto, Peter Choyke and colleagues Philips provides NIH access to software code, latest imaging technology, and 2 onsite physicists to develop quantitative MRI NIH provides Philips with real-time feedback: what does, does not work Jointly develop innovative technologies including fusion MRI and ultrasound fusion biopsy 6

Diagnosis NIH MRI scan April 16, endorectal and phased array surface coil – Two suspicious sites identified in the prostate “Small subtle age lesion in the midgland…making this a moderate risk lesion” – Family history of brothers with prostate cancer increases this as risk NIH Biopsy May 19 – Biopsy of 18 sites included usual random sampling of prostate but also targeted within the 18 the two suspicious sites found by the MRI – Biopsy revealed 5 sites positive for prostate cancer including the 2 sites identified in the MRI – Prostate cancer “Gleason Score” 6 (3+3), easier to treat compared to higher Gleason scores 7

Treatment Prostate surgery July 27, Johns Hopkins, Baltimore – Released from hospital July 29 (food was pretty good) Successful Operation: – Post-surgery pathology report cited “negative margins”, indicating cancer fully contained in prostate – First post-surgery PSA reading was < 0.1 nanograms per milliliter of blood; threshold of 0.2ng or less is success Indicators point to cancer cure 8

CONCLUSIONS Cancer touches many lives – Some families have more than their share – Cancer creates sadness and trauma far beyond what is seen in dry statistics/actuarial tables; there are real people behind these numbers!! Cancer remains a deadly threat but technology advances across a broad front towards early detection, treatment, and hopefully cure. NIH CRADA with Philips Medical Systems – Fuses data from MRI/Magnetic Resonance Imaging and prostate biopsy – Provides a targeted approach to biopsy site selection rather than purely random sample approach Purely random biopsy site selection can lead to false negative findings, false sense of security when in fact cancer can be present My early cancer detection including the NIH MRI study, and subsequent treatment, is giving me the best chance for cancer cure. 9

IF ANYONE WOULD LIKE TO DISCUSS DEALING WITH PROSTATE CANCER I WOULD BE HAPPY TO TALK TO YOU: JOHN EMOND, INNOVATIVE PARTNERSHIPSPROGRAM, NASA HEADQUARTERS PHONE: